GoAI
Get started
Universe Pharmaceuticals Inc. logo

Universe Pharmaceuticals Inc.

UPC

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$5.30

−$0.03 · -0.56%

Aug 21, 4:00 PM ET

UPC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

67

Undervalued

Momentum

54

Neutral

Sentiment

54

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CN
CEO
Gang Lai
Listed since
Mar 23, 2021
Employees
216

Market position

Day range

Current $5.30

52-week range

Current $5.30

Open
$5.18
Previous close
$5.33
Volume
4.72K
0× average
Average volume
1.62M
Average daily volume
Market cap
3.35M USD
Beta
1.53
Market reference 1
50-day average
$4.8048
+10.31% above average
200-day average
$3.7532
+41.21% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-24.32M USD
P/E (TTM)
-1.54×
P/B (TTM)
0.05×
P/S (TTM)
0.19×
EV / EBITDA
8.32×
Earnings yield
-25137.98%
Free cash flow yield
-36963.68%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
35.86%
Operating margin
-11.78%
Net margin
-10.95%
Return on equity
-6.54%
Return on assets
-5.30%
Return on invested capital
-4.46%

Financial health

Debt / equity
0.17×
Current ratio
4.07×
Altman Z-score
1.02
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends64%27%-10%-47%Gross margin, FY2021: 52.78%Gross margin, FY2022: 54.53%Gross margin, FY2023: 31.93%Gross margin, FY2024: 26.37%Gross margin, FY2025: 35.28%Operating margin, FY2021: 28.32%Operating margin, FY2022: -17.49%Operating margin, FY2023: -10.92%Operating margin, FY2024: -34.83%Operating margin, FY2025: -16.33%Net margin, FY2021: 23.59%Net margin, FY2022: -21.76%Net margin, FY2023: -19.08%Net margin, FY2024: -37.90%Net margin, FY2025: -20.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 52.78%. Gross margin FY2022 54.53%. Gross margin FY2023 31.93%. Gross margin FY2024 26.37%. Gross margin FY2025 35.28%. Operating margin FY2021 28.32%. Operating margin FY2022 -17.49%. Operating margin FY2023 -10.92%. Operating margin FY2024 -34.83%. Operating margin FY2025 -16.33%. Net margin FY2021 23.59%. Net margin FY2022 -21.76%. Net margin FY2023 -19.08%. Net margin FY2024 -37.90%. Net margin FY2025 -20.56%.

Income trends

Revenue

17.86M USD-22.44%

Operating income

−2.92M USD+63.64%

Net income

−3.67M USD+57.92%
Income trends across reported periods53.65M USD30.97M USD8.28M USD−14.41M USDRevenue, FY2021: 47.98M USDRevenue, FY2022: 40.14M USDRevenue, FY2023: 32.31M USDRevenue, FY2024: 23.02M USDRevenue, FY2025: 17.86M USDOperating income, FY2021: 13.59M USDOperating income, FY2022: −7.02M USDOperating income, FY2023: −3.53M USDOperating income, FY2024: −8.02M USDOperating income, FY2025: −2.92M USDNet income, FY2021: 11.32M USDNet income, FY2022: −8.74M USDNet income, FY2023: −6.16M USDNet income, FY2024: −8.73M USDNet income, FY2025: −3.67M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 47.98M USD. Revenue FY2022 40.14M USD. Revenue FY2023 32.31M USD. Revenue FY2024 23.02M USD. Revenue FY2025 17.86M USD. Operating income FY2021 13.59M USD. Operating income FY2022 −7.02M USD. Operating income FY2023 −3.53M USD. Operating income FY2024 −8.02M USD. Operating income FY2025 −2.92M USD. Net income FY2021 11.32M USD. Net income FY2022 −8.74M USD. Net income FY2023 −6.16M USD. Net income FY2024 −8.73M USD. Net income FY2025 −3.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue17.86M USD23.02M USD32.31M USD40.14M USD47.98M USD
Cost of goods sold11.56M USD16.95M USD21.99M USD18.25M USD22.66M USD
Gross profit6.3M USD6.07M USD10.32M USD21.89M USD25.33M USD
Research and development671.76K USD3.03M USD4.86M USD7.62M USD5.47M USD
Selling, general, and administrative8M USD10.44M USD9M USD21.3M USD6.27M USD
Operating expenses9.22M USD14.09M USD13.84M USD28.91M USD11.74M USD
Interest expense232.04K USD278.17K USD156.79K USD162.4K USD101.6K USD
Depreciation and amortization517.43K USD485.73K USD508.79K USD533.95K USD446.88K USD
Operating income−2.92M USD−8.02M USD−3.53M USD−7.02M USD13.59M USD
Net income−3.67M USD−8.73M USD−6.16M USD−8.74M USD11.32M USD

Company facts updated Aug 24, 2026.

UPC news

globenewswire.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that…

Read source
globenewswire.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that…

Read source
businesswire.com

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 24, 2025

1:40

Stock split

Effective Nov 18, 2024

1:15

Stock split

Effective Jul 28, 2023

1:6

UPC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research UPC

research.disclaimer